The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 2, 2007, Pages 626-635

  Coelho, Rochelle P ^a   Payne, Shawn G ^a   Bittman, Robert ^b   Spiegel, Sarah ^a   Sato Bigbee, Carmen ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOPROTECTION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; IMMUNOSUPPRESSIVE AGENTS; MICROGLIA; NEUROTROPHIN 3; OLIGODENDROGLIA; PHOSPHORYLATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROPYLENE GLYCOLS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; SPHINGOSINE; STEM CELLS;

EID: 35548984947     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.123927     Document Type: Article

References (44)

1. Albert R, Hinterding K, Brinkmann V, Guerini D, Muller-Hartwieg C, Knecht H, Simeon C, Streiff M, Wagner T, Welzenbach K, et al (2005) Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer: identification, chemical proof, and biological characterization of the biologically active species and its enantiomer. J Med Chem 48:5373-5377.
2. Barnett MH and Prineas JW (2004) Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 55:458-468.
3. Barres BA, Schmid R, Sendnter M, and Raff MC (1993) Multiple extracellular signals are required for long-term oligodendrocyte survival. Development 118:283-295.
4. Block ML, Zecca L, and Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8:57-69.
5. Brinkmann V and Lynch KR (2002) FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 14:569-575.
6. Chiba K, Hoshino Y, Suzuki C, Masubuchi Y, Yanagawa Y, Ohtsuki M, Sasaki S, and Fujita T (1996) FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplant Proc 28:1056-1059.
7. Chiba K, Matsuyuki H, Maeda Y, and Sugahara K (2006) Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. Cell Mol Immunol 3:11-19.
8. Chiba K, Yanagawa Y, Masubuchi Y, Kataoka H, Kawaguchi T, Ohtsuki M, and Hoshino Y (1998) FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 160:5037-5044.
9. Cui QL, Fogle E, and Almazan G (2006) Muscarinic acetylcholine receptors mediate oligodendrocyte progenitor survival through Src-like tyrosine kinases and PI3K/Akt pathways. Neurochem Int 48:383-393.
10. Ebner S, Dunbar M, and McKinnon RD (2000) Distinct roles for PI3K in proliferation and survival of oligodendrocyte progenitor cells. J Neurosci Res 62:336-345.
11. Fragoso G, Martinez-Bermudez AK, Liu HN, Khorchid A, Chemtob S, Mushynski WE, and Almazan G (2004) Developmental differences in HO-induced oligodendrocyte cell death: role of glutathione, mitogen-activated protein kinases and caspase 3. J Neurochem 90:392-404.
12. Fujino M, Funeshima N, Kitazawa Y, Kimura H, Amemiya H, Suzuki S, and Li XK (2003) Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 305:70-77.
13. Herr DR and Chun J (2007) Effects of LPA and S1P on the nervous system and implications for their involvement in disease. Curr Drug Targets 8:155-167.
14. Hida H, Nagano S, Takeda M, and Soliven B (1999) Regulation of mitogen-activated protein kinases by sphingolipid products in oligodendrocytes. J Neurosci 19:7458-7467.
15. Hu Y, Wang X, Zeng L, Cai DY, Sabapathy K, Goff SP, Firpo EJ, and Li B (2005) ERK phosphorylates p66shcA on Ser36 and subsequently regulates p27kip1 expression via the Akt-FOXO3a pathway: implication of p27kip1 in cell response to oxidative stress. Mol Biol Cell 16:3705-3718.
16. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
17. Jean I, Lavialle C, Barthelaix-Pouplard A, and Fressinaud C (2003) Neurotrophin-3 specifically increases mature oligodendrocyte population and enhances remyelination after chemical demyelination of adult rat CNS. Brain Res 972:110-118.
18. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, and Radue EW (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355:1124-1140.
19. Kataoka H, Sugahara K, Shimano K, Teshima K, Koyama M, Fukunari A, and Chiba K (2005) FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2:439-448.
20. Keirstead HS and Blakemore WF (1999) The role of oligodendrocytes and oligodendrocyte progenitors in CNS remyelination. Adv Exp Med Biol 468:183-197.
21. Lan YY, De Creus A, Colvin BL, Abe M, Brinkmann V, Coates PT, and Thomson AW (2005) The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am J Transplant 5:2649-2659.
22. Lu X and Bittman R (2006) Enantioselective synthesis of the immunosuppressive lipid FTY720. Tetrahedron Lett 47:825-827.
23. Lucchinetti CF, Bruck W, and Lassmann H (2004) Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol 56:308.
24. Lucchinetti CF, Parisi J, and Bruck W (2005) The pathology of multiple sclerosis. Neurol Clin 23:77-105, vi.
25. Maki T, Gottschalk R, and Monaco AP (2002) Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice. Transplantation 74:1684-1686.
26. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, et al. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346-349.
27. Matsuda S, Minowa A, Suzuki S, and Koyasu S (1999) Differential activation of c-Jun NH2-terminal kinase and p38 pathways during FTY720-induced apoptosis of T lymphocytes that is suppressed by the extracellular signal-regulated kinase pathway. J Immunol 162:3321-3326.
28. McQualter JL and Bernard CC (2007) Multiple sclerosis: a battle between destruction and repair. J Neurochem 100:295-306.
29. McTigue DM, Horner PJ, Stokes BT, and Gage FH (1998) Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. J Neurosci 18:5354-5365.
30. Meno-Tetang GM, Li H, Mis S, Pyszczynski N, Heining P, Lowe P, and Jusko WJ (2006) Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos 34:1480-1487.
31. Mizushima T, Ito T, Kishi D, Kai Y, Tamagawa H, Nezu R, Kiyono H, and Matsuda H (2004) Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis. Inflamm Bowel Dis 10:182-192.
32. Müller H, Hofer S, Kaneider N, Neuwirt H, Mosheimer B, Mayer G, Konwalinka G, Heufler C, and Tiefenthaler M (2005) The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol 35:533-545.
33. Mullershausen F, Craveiro LM, Shin Y, Cortes-Cros M, Bassilana F, Osinde M, Wishart WL, Guerini D, Thallmair M, Schwab ME, et al. (2007) Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J Neurochem 102:1151-1161.
34. Nomura M, Kaji A, Ma WY, Zhong S, Liu G, Bowden GT, Miyamoto KI, and Dong Z (2001) Mitogen- and stress-activated protein kinase 1 mediates activation of Akt by ultraviolet B irradiation. J Biol Chem 276:25558-25567.
35. Osinde M, Mullershausen F, and Dev KK (2007) Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology 52:1210-1218.
36. Pang Y, Cai Z, and Rhodes PG (2000) Effects of lipopolysaccharide on oligodendrocyte progenitor cells are mediated by astrocytes and microglia. J Neurosci Res 62:510-520.
37. Pang Y, Zheng B, Fan LW, Rhodes PG, and Cai Z (2007) IGF-1 protects oligodendrocyte progenitors against TNFα-induced damage by activation of PI3K/Akt and interruption of the mitochondrial apoptotic pathway. Glia 55:1099-1107.
38. Payne SG, Oskeritzian CA, Griffiths R, Subramanian P, Barbour SE, Chalfant CE, Milstien S, and Spiegel S (2007) The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood 109:1077-1085.
39. Saini HS, Coelho RP, Goparaju SK, Jolly PS, Maceyka M, Spiegel S, and Sato-Bigbee C (2005) Novel role of sphingosine kinase 1 as a mediator of neurotrophin-3 action in oligodendrocyte progenitors. J Neurochem 95:1298-1310.
40. Sato-Bigbee C, Pal S, and Chu AK (1999) Different neuroligands and signal transduction pathways stimulate CREB phosphorylation at specific developmental stages along oligodendrocyte differentiation. J Neurochem 72:139-147.
41. Trapp BD, Ransohoff R, and Rudick R (1999) Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 12:295-302.
42. Webb M, Tham CS, Lin FF, Lariosa-Willingham K, Yu N, Hale J, Mandala S, Chun J, and Rao TS (2004) Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 153:108-121.
43. Zemann B, Kinzel B, Muller M, Reuschel R, Mechtcheriakova D, Urtz N, Bornancin F, Baumruker T, and Billich A (2006) Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 107:1454-1458.
44. Zhao C, Fancy SP, Magy L, Urwin JE, and Franklin RJ (2005) Stem cells, progenitors and myelin repair. J Anat 207:251-258.